Registration Dossier

Toxicological information

Endpoint summary

Currently viewing:

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Endpoint conclusion:
adverse effect observed (sensitising)
Additional information:

No studies are available for dichromium tris(chromate). The following information is taken from the EU RAR:

Skin sensitisation resulting from occupational contact with Cr(VI) compounds is relatively common in humans. This has also been demonstrated in patch testing of contact dermatitis patients and in investigations of various occupational groups. In addition, the skin sensitisation potential of Cr (VI) compounds has been clearly demonstrated in standard and modified guinea pig maximisation tests and in the mouse ear swelling test. The current understanding of the mechanism involved in the sensitisation indicates that Cr (III) is the ultimate hapten. Skin contact with Cr (VI) leads to penetration of Cr (VI) into the skin where it is reduced to Cr (III). There is some evidence for cross-reactivity between Cr (III) and Cr (VI); Cr(VI)-sensitised subjects may also react to Cr (III). Overall, it is not possible to reliably determine a threshold for either induction or challenge in an exposed population using the available data, however it is assumed that all water soluble Cr (VI) compounds are human skin sensitisers.


Migrated from Short description of key information:
No studies are available and testing of this group of compounds for skin sensitisation is not proposed, based on the low pH and classification as corrosive. Data from human exposure indicate that the water-soluble Cr(VI) compounds are skin sensitiers, therefore testing is not required.

Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
adverse effect observed (sensitising)

Justification for classification or non-classification

Dichromium tris(chromate) is listed on Regulation (EC) No 1272/2008 as a Category 1 Skin Sensitiser (with additional Note T) based on effects observed in humans exposed occupationally to other hexavalent chromium compounds. No change to this classification is proposed.